secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001140361-22-037955
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed raises $775M via term loan, royalty deal, and equity offering to fund pipeline
--------------------------------------------------------------------------------

- $350M senior secured term loan from Pharmakon Advisors, maturing Oct 2027, at SOFR+7.75% (floor 2.5%).
- $150M synthetic royalty deal with OrbiMed: 4-4.5% of ARIKAYCE sales + 0.75% of brensocatib sales, capped at 1.8-1.9x.
- $275M equity offering: 13.75M shares at $20.00; closing expected Oct 21, 2022.
- Pro forma cash and marketable securities ~$1.3B; proceeds to fund ARIKAYCE commercial launch, brensocatib readiness, and R&D.
- Term loan and royalty financing closed Oct 19, 2022; equity underwriting with J.P. Morgan and SVB Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122037955/0001140361-22-037955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122037955/ny20005570x4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-037955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer